Kornitzer Capital Management INC Boosted Stake in Portola Pharmaceuticals INC (PTLA) by $10.96 Million

March 18, 2018 - By Vivian Park

Investors sentiment increased to 2.16 in 2017 Q3. Its up 0.85, from 1.31 in 2017Q2. It improved, as 20 investors sold PTLA shares while 37 reduced holdings. 38 funds opened positions while 85 raised stakes. 56.33 million shares or 15.80% more from 48.64 million shares in 2017Q2 were reported. Principal Fincl Incorporated has invested 0% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Goldman Sachs Group Inc stated it has 432,308 shares. Sg Americas Securities Llc holds 6,079 shares. Alps Advsr invested in 0.02% or 56,788 shares. Victory Cap Mngmt owns 1,265 shares. First Mercantile Trust invested in 0.07% or 7,500 shares. Public Employees Retirement Association Of Colorado invested in 0% or 11,029 shares. Nicholas Partners Limited Partnership invested in 64,005 shares. Temasek (Private) has 1.54% invested in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). United Svcs Automobile Association accumulated 106,573 shares or 0.02% of the stock. Dimensional Fund Advsr Lp, a Texas-based fund reported 12,247 shares. Eam Invsts Lc invested in 33,456 shares. Great West Life Assurance Co Can, a Manitoba – Canada-based fund reported 5,798 shares. Numeric Limited Liability Company has invested 0.07% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Rhumbline Advisers stated it has 64,689 shares or 0.01% of all its holdings.

Since December 15, 2017, it had 0 buys, and 2 insider sales for $607,613 activity. On Monday, March 12 Fu Tao sold $43,663 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 1,135 shares.

Kornitzer Capital Management Inc increased its stake in Portola Pharmaceuticals Inc (PTLA) by 38.66% based on its latest 2017Q3 regulatory filing with the SEC. Kornitzer Capital Management Inc bought 202,925 shares as the company’s stock rose 22.73% with the market. The institutional investor held 727,812 shares of the health care company at the end of 2017Q3, valued at $39.32 million, up from 524,887 at the end of the previous reported quarter. Kornitzer Capital Management Inc who had been investing in Portola Pharmaceuticals Inc for a number of months, seems to be bullish on the $2.28 billion market cap company. The stock decreased 3.54% or $1.28 during the last trading session, reaching $34.83. About 1.71 million shares traded or 31.28% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has risen 51.17% since March 18, 2017 and is uptrending. It has outperformed by 34.47% the S&P500.

Kornitzer Capital Management Inc, which manages about $11.35B and $5.73B US Long portfolio, decreased its stake in Align Technology Inc (NASDAQ:ALGN) by 19,795 shares to 265,524 shares, valued at $49.46M in 2017Q3, according to the filing. It also reduced its holding in Boeing Co. (NYSE:BA) by 13,930 shares in the quarter, leaving it with 283,806 shares, and cut its stake in Verisk Analytics Inc (NASDAQ:VRSK).

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 7 analysts covering Portola Pharmaceuticals (NASDAQ:PTLA), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. Portola Pharmaceuticals had 39 analyst reports since August 5, 2015 according to SRatingsIntel. Oppenheimer maintained the shares of PTLA in report on Wednesday, December 13 with “Buy” rating. Citigroup maintained the stock with “Buy” rating in Monday, June 26 report. The firm has “Buy” rating given on Thursday, August 10 by Oppenheimer. The rating was maintained by Credit Suisse with “Hold” on Thursday, August 10. The stock of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has “Outperform” rating given on Thursday, August 24 by Credit Suisse. Oppenheimer maintained the shares of PTLA in report on Tuesday, March 13 with “Buy” rating. On Friday, February 24 the stock rating was upgraded by Oppenheimer to “Outperform”. The firm has “Buy” rating given on Friday, August 4 by Oppenheimer. The rating was maintained by Oppenheimer with “Buy” on Monday, August 28. The rating was maintained by Oppenheimer with “Buy” on Sunday, July 23.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.